Imugenes Oncolytic Virotherapy CF33 Patent Allowed in the US

Imugene Limited (ASX: IMU), a clinical stage immunooncology company, has been granted a Notice of Allowance from the US Patent and Trademark Office (USPTO) for its patent application protecting oncolytic virotherapy CF33. The patent, named "Composition and Uses of CHIMERIC POXVIRUS," grants Imugene exclusive rights for the method of composition and method of use of their licensed oncolytic virotherapy until 2037.

Professor Yuman Fong from the City of Hope is the developer of CF33, a chimeric vaccinia poxvirus. Oncolytic viruses are designed to selectively target and destroy tumor cells while activating the immune system against cancer, potentially improving clinical response and survival rates. Imugene's receipt of this patent allowance is seen as a significant milestone, particularly given the importance of the US healthcare market.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com